Company Encyclopedia
View More
name
Invesco Biotechnology & Genome ETF
PBE.US
News
View More

16:42 ET Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually

Illumina and MyOme have announced a collaboration and strategic investment to support MyOme's clinical trial, aiming to save U.S. healthcare $200 billion annually. The partnership combines Illumina's sequencing technology with MyOme's AI-integrated risk models to advance precision medicine for early detection and prevention. The MPH trial will begin enrollment in 2026, focusing on whole-genome sequencing and risk models for chronic conditions, cancers, and rare diseases.

prnewswire·
US
ILMN
-1.15%
prnewswire·
US
ILMN
-1.15%

Illumina’s AI Genomics Partnership With MyOme Might Change The Case For Investing In Illumina (ILMN)

Illumina and MyOme have announced a collaboration to support MyOme’s Proactive Health Trial, combining whole-genome sequencing with AI-integrated risk models to improve health outcomes and reduce costs. This partnership aims to enhance preventive care and rare disease diagnostics in the US healthcare system. The collaboration underscores Illumina’s focus on AI-enabled genome sequencing, despite ongoing challenges in clinical adoption, research demand, and competition. Illumina projects $4.8 billion revenue and $873.5 million earnings by 2028, with a fair value estimate of $119.84 per share, reflecting an 11% downside to its current price.

Simplywall·
US
ILMN
-1.15%
Simplywall·
US
ILMN
-1.15%

Alnylam Pharmaceuticals: Hold Rating Due to Sales Projections Falling Short of Consensus

Morgan Stanley analyst Michael Ulz maintains a Hold rating on Alnylam Pharmaceuticals with a $495 price target due to sales projections falling short of consensus. Estimated sales for Amvuttra and the TTR franchise are below expectations, despite aligning with company guidance. Alnylam's stock price increased by 30.49% over six months. Preliminary sales figures for Q4 and full-year 2025 are expected in January.

Tip Ranks·
US
ALNY
-3.65%
Tip Ranks·
US
ALNY
-3.65%

Stance Capital LLC Takes Position in Gilead Sciences, Inc. $GILD

Stance Capital LLC acquired 11,825 shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, valued at approximately $1,311,000. Other hedge funds also increased their positions in Gilead Sciences. The company's stock opened at $120.40 on Friday, with a 52-week range of $88.57 to $128.70. Gilead Sciences reported quarterly earnings of $2.47 per share, beating estimates, and announced a quarterly dividend of $0.79 per share. Insiders sold 135,757 shares valued at $16,616,127 last quarter. Analysts forecast growth for Gilead Sciences.

Market Beat·
US
GILD
-2.28%
Market Beat·
US
GILD
-2.28%

Nikko Asset Management Americas Inc. Increases Stake in Illumina, Inc. $ILMN

Nikko Asset Management Americas Inc. increased its stake in Illumina, Inc. by 28.8% in Q2, owning 867,981 shares valued at $82.8 million. Other institutional investors also adjusted their positions in Illumina. Analysts have mixed ratings on the stock, with an average "Hold" rating and a target price of $115. Illumina's recent earnings exceeded expectations, with a reported EPS of $1.34 and revenue of $1.08 billion.

Market Beat·
US
ILMN
-1.15%
Market Beat·
US
ILMN
-1.15%
© 2025 Longbridge｜Disclaimer